This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies are
encouraged to visit:
Author's personal copy
Rag2−/−γ-chain−/−mice as hosts for human vessel transplantation and allogeneic
human leukocyte reconstitution
Silke Abele-Ohla, Martina Leisb, Shohreh Mahmoudianb, Michael Weyanda,
Thomas Stammingerb,1, Stephan M. Ensmingera,⁎,1
aDepartment of Cardiac Surgery, Friedrich-Alexander University, Erlangen-Nürnberg, Krankenhausstrasse 12, 91054 Erlangen, Germany
bInstitute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, Germany
a b s t r a c ta r t i c l e i n f o
Received 21 December 2009
Received in revised form 30 March 2010
Accepted 5 April 2010
Background: Rodent models are a very helpful tool to investigate immunological mechanisms in allograft
rejection. The aim of this study was to compare two different immunodeficient recipients in a humanized
mouse model of arterial xenotransplantation in terms of reconstitution of the human immune system and
rejection of the arterial graft.
Methods: Side branches of human mammary artery were transplanted as infrarenal aortic interposition grafts
into C.B-17–SCID beige and C57BL/6–Rag2−/−γc−/−recipients. 7 days after surgery mice were reconstituted
with 5×107human peripheral blood mononuclear cells (hu PBMCs) and 30 days after reconstitution mice
were sacrificed and histologic analysis was performed. Peripheral blood and splenocytes were investigated
by FACS and ELISA analysis to ensure engraftment of human CD45+cells.
Results: Transplant arteriosclerosis developed in non-PBMC-reconstituted C.B-17–SCID beige mice (intimal
proliferation: 36.31±4.37%), but significantly less in C57BL/6–Rag2−/−γc−/−recipients (intimal
proliferation: 12.26±5.21%). After reconstitution with 5×107unfractionated human PBMCs both mouse
strains showed intima proliferation 30 days after reconstitution (C.B-17–SCID beige: 28.49±7.95% and
C57BL/6–Rag2−/−γc−/−: 44.58±11.08%). Whereas only very few human CD45+cells were found in mouse
blood and spleen of C.B-17–SCID beige mice, C57BL/6–Rag2−/−γc−/−mice revealed a reliable
reconstitution. In addition, levels of human IgG and IgM within the peripheral blood were markedly higher
Conclusion: In this study we can show, that the use of C57BL/6–Rag2−/−γc−/−mice may be advantageous
compared to C.B-17–SCID beige recipients in a humanized mouse model of vessel transplantation.
© 2010 Elsevier B.V. All rights reserved.
Small animal models have been very helpful to investigate
underlying immunological mechanisms in transplantation, but cer-
tain limitations are unavoidable because of species-specific differ-
ences to humans. Immunodeficient mice harboring human cells or
tissues are frequently referred to as “humanized mice”. They are a
promising tool for studying complex mechanisms in human biology
and at least may partly overcome these species-specific differences.
Mice bearing human immune systems have been developed to
investigate immune-mediated disease pathogenesis [1,2] and alloge-
neic tissue rejection and tolerance in vivo [3–5].
About 20 years ago, the original “SCID-hu” model was developed by
McCune et al. using C.B-17–SCID mice as recipients for human
hematopoietic tissues including fetal liver, bone, and/or thymus
originating from human fetuses [6–8].
Engrafted human hematopoietic tissue resulted in low levels of
human T and B cells that were able to produce a primary antibody
response when autologous fetal skin, serving as an additional source
of dendritic cells, was coengrafted along with thymus, bone marrow,
and lymph node . Adoptive transfer of peripheral blood mononu-
clear cells (PBMC) in this same mouse strain supported low levels of
engraftment of T, B and dendritic cells .
Further refinements of this system were achieved by introducing a
recipients to accept higher levels of mature human T and B cells
[11,12]. Technical advances such as the transfer of isolated hemato-
poietic stem cells (HSC) in C.B-17–SCID and NOD–SCID mice [13,14]
and the development of more severely immunodeficient mouse lines
lacking the common cytokine receptor gamma chain (γ-chain)
Transplant Immunology 23 (2010) 59–64
⁎ Corresponding author. Tel.: +49 9131 8533590; fax: +49 9131 8532768.
E-mail address: firstname.lastname@example.org (S.M. Ensminger).
1Both senior authors equally contributed to the work.
0966-3274/$ – see front matter © 2010 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/trim
Author's personal copy
[15,16] enhanced theapplicability of humanized mice for studyingthe
human immune system.
Nowadays, several models using C.B-17–SCID/beige immunodefi-
cient mouse hosts in which human memory T-cell responses to artery
graft tissue can be studied in vivo have been developed [4,17–19].
Despite an essentially absent adaptive immune system, C.B-17–SCID
animals are still significantly resistant to adoptive transfer of human
peripheral blood lymphocytes (PBL). Indeed, further studies showed
that resistance to adoptive transfer of human PBL was reduced in
animals treated with antibody to asialo GM1, which depletes NK cells,
or in C.B-17–SCID animals that also have the ‘beige’ mutation that
impairs NK-cell-function [4,17,18,20]. The SCIDhu model is nowadays
a well established system for the study of human alloresponses in
vivo, and particularly using the technique of xenografting human
arteries into these mice, great progress in the understanding of
immune-mediated damage to vascularised transplants has been
achieved . However, inherent problems of the model have left
researchers dissatisfied with several aspects of the experimental
system, e.g. an important shortcoming in C.B-17–SCID/beige recipi-
ents is the fact that they have to be injected with fairly high human
cell numbers (up to 108) and cells other than CD4+T cells engraft
Therefore, it was the aim of the present study to directly compare
C.B-17–SCID/beige animals with C57BL/6–Rag2−/−γc−/−mice lack-
ing T, B and NK cells  as recipients of human arterial transplants
reconstituted with human PBMCs from the peripheral blood of adult
donors and evaluate if this modification improves the experimental
humanized mouse system of arterial transplantation. Here we can
show, that C57BL/6–Rag2−/−γc−/−mice offer technical advantages
over C.B-17–SCID/beige recipients as they much more readily accept
human blood PBMCs, show improved reconstitution rates with lower
levels of human PBMCs and more reliably reject human arterial
transplants. In addition, vascular lesions were not detected in C57BL/
6–Rag2−/−γc−/−recipients in the absence of cell transfer. Therefore,
the use of C57BL/6–Rag2−/−γc−/−mice may be advantageous
compared to C.B-17–SCID/beige recipients in a humanized mouse
2. Methods and materials
Original breeding pairs for C.B-17–SCID beige as well as C57BL/6–
Rag2−/−γc−/−mice were obtained from Charles River (Sulzbach,
Germany) and Taconic (Germantown, N.Y., USA). Mice were aged
between 6–12 weeks at the time of experimental use and were bred
and maintained at the central animal facility of the University of
Erlangen-Nuernberg (Franz–Penzoldt–Zentrum) in isolated ventilat-
ed cages with sterilized food, water and bedding. All experimental
animals were treated in accordance with institutional and state
guidelines. In addition, mice were maintained on trimethoprim
(8 mg/kg) and sulfamethoxazole (40 mg/kg) in their drinking water.
2.2. Measurement of mouse and human immunoglobulin
The level of mouse immunoglobulin (mu Ig and IgM) was
quantified by ELISA technique at 4 weeks of age as described in a
previous publication . Mice with immunoglobulin levels superior
to 1 µg/ml were considered “leaky” and were not used for experi-
ments. Human immunoglobulin (IgM and IgG) was measured by an
enzyme linked immunosorbent assay (ELISA). Blood samples were
taken from the mouse retroorbital plexus and collected in serum
microtainers (BD Microtainer SST, Schubert, Wackersdorf, Germany).
Briefly, ELISA plates (NUNC MaxiSorp plates) were coated with
a polyclonal rabbit anti-human IgG+IgM antibody (Jackson
ImmunoSearch Laboratories, Suffolk, UK). After blocking of unspecific
binding capacities by incubation with 5% fetal calf serum in phosphate
buffered saline, dilutions of mouse sera were applied together with
serial dilutions of control sera with known immunoglobulin contents.
After extensive washing,bound human antibodies were detected via a
peroxidase-conjugated anti-human IgG+IgM antibody (Dianova,
Hamburg, Germany) together with TMB peroxidase substrate
(Medac, Wedel, Germany). Human immunoglobulin concentrations
in mouse sera were calculated from standard curves derived from the
samples with known immunoglobulin contents.
2.3. Abdominal transplantation of human mammary artery segments
by Lorber et al. . Briefly, size-matched segments of side branches
from the human mammary artery obtained during routine CABG-
surgery were transplanted as infrarenal aortic interposition grafts into
and distal end to end anastomosis was performed with single
interrupted sutures using 11-0 monofilament nylon suture. Before
closure of the abdomen, hemostasis and blood flow through the
transplanted arterial segment were confirmed and warm sterile saline
was administered into the abdomen.
2.4. Purification of human PBMCs
Human buffy coats were obtained from the regional blood bank
(Blood bank Suhl, Institute for Transfusion Medicine, Germany). Cells
were tested for a variety of pathogens, including HIV, HCV and CMV to
exclude infections. Immediately upon receipt, mononuclear cells were
purified by Ficoll density centrifugation using Lymphoprep (Axis-
Shield, Oslo, Norway) as described by the manufacturer. After
quantification under Trypan blue exclusion a defined number of
cells (5×107) was resuspended in endotoxin-free phosphate buffered
saline (volume of 300 µl) and used for intraperitoneal (i.p.) injection
2.5. Determination of human lymphocytes
The success of lymphocyte engraftment was assessed by flow
cytometry 30 days after PBMC administration. For this, either
peripheral blood was collected by puncture of the retroorbital plexus
using EDTA-containing 1.5 ml tubes. Alternatively, spleen cells were
harvested from sacrificed animals. Flow cytometry was performed on
a FACScalibur flow cytometer according to standard protocols. The
directly labelled monoclonal antibodies (allophycocyanin [APC],
fluorescein-isothiocyanate [FITC], or phycoerythrin [PE] conjugated)
were specific for human CD45 or murine CD45. Directly-labelled
isotype-matched monoclonal antibodies were used as controls. All
antibodies were purchased from Becton Dickinson (BD Biosciences,
Heidelberg, Germany). Two-colour fluorescence was used to measure
PBMC engraftment was considered successful when a distinct
population of human CD45+cells was measured, consisting of more
than 0.1% of the total circulating leukocyte population concerning
mouse blood samples or more than 0.5% concerning mouse spleen cell
2.6. Morphometric analysis of the mammary artery graft
Mammary artery grafts were removed under anaesthesia on day 30
after transplantation. Grafts were perfused with saline and were flash
frozen in OCT medium (Tissue-Tek®, Sakura, Netherlands) in liquid
nitrogen for morphometric analysis of 7 µm cryostat sections. Five
cross-sections from different regions of each graft harvested at day 30
S. Abele-Ohl et al. / Transplant Immunology 23 (2010) 59–64
Author's personal copy
conventional light microscope (original magnification ×200). For the
morphometric analysis of the degree of intimal thickening the area
within the lumen and the internal elastic lamina was circumscribed
as previously described . All image analysis was carried out using
ANAlysis® Image Analysis software (Olympus, Germany).
2.7. Statistical analysis
Results are given as the mean per group±SEM, which was derived
from the mean per graft. The data were analysed using a two-tailed
unpaired Student's test. A p-value of b0.05 was considered as
3.1. SCID/beige recipients reject mammary artery grafts in the absence of human PBMCs
In a first set of experiments age matched (6–8 weeks) C.B17–SCID/beige and
C57BL/6-Rag2−/−γc−/−received an abdominal human mammary artery graft and no
reconstitution of human PBMCs. Prior to the experiment, C.B17–SCID/beige recipients
were screened for ‘leakyness’ and respective animals were excluded from further
experimental use. Interestingly, C.B17–SCID/beige recipients showed prominent intima
proliferation even in the absence of human PBMCs (Intima proliferation: 36.31±
4.37%) (Fig.1A). In contrast, C57BL/6–Rag2−/−γc−/−mice undergoing the same
procedure demonstrated almost no signs of vascular lesions in the absence of human
PBMCs (Intima proliferation: 12.26±5.21%) (Fig.1B). After reconstitution with
5×107human PBMCs both experimental groups developed significant levels of
transplant arteriosclerosis (Fig. 1C, D).
3.2. Rag2−/−γc−/−recipients show higher levels of circulating CD45+cells after
reconstitution with human PBMCs
Initial reconstitution experiments with different doses of human PBMCs
revealed, that after transfer of 5×107PBMCs stable reconstitution levels were seen
in C57BL/6–Rag2−/−γc−/−recipients and no signs of GVHD like weight loss, bad fur
structure or changes in skin, liver and gut could be detected (data not shown). There-
fore, on day 7 after implantation of the mammary artery graft, C.B17–SCID/beige and
C57BL/6–Rag2−/−γc−/−recipients were reconstituted with 5×107hu PBMCs.
30 days after i.p. PBMC-reconstitution almost no human CD45+cell-chimerism
was detectable in the blood (0.13±0.48% human CD45+cells) or spleen (0.36±
0.87% human CD45+cells) of SCID/beige recipients (Fig. 2). C57BL/6–Rag2−/−γc−/−
mice of the experimental group reconstituted with human PBMCs showed 3.13±
1.74% human CD45+cells in the blood and 12.23±6.63% human CD45+cells in the
spleen 30 days after reconstitution (Fig. 2). (*=pb0.05 vs. reconstituted C.B17–
SCID/beige; **=pb0.05 vs. reconstituted C.B17–SCID/beige (n=5)).These results
were paralleled by levels of human IgG and IgM of 108±22 µg/ml in C.B17–SCID/
beige recipients and 748±27 µg/ml in C57BL/6–Rag2−/−γc−/−recipients (Fig. 3).
(*=pb0.05 vs. reconstituted C.B17–SCID/beige/(n=5)).
3.3. Rag2−/−γc−/−recipients display more stable rejection responses of the human
The read out and therefore most important aspect of this experimental model is a
reliable rejection response of the human vascular mammary artery graft after
reconstitution with human PBMCs. Overall complication rates of this study were 9.2%
(SCID) and 8.5% (RAG-2), the most frequent complication in both groups being
thrombosis of the aortic graft (n=4) and one late death of the recipient due to other
causes. None of the recipient-mice showed any kind of haemorrhage or major
postoperative bleeding. Again, there was a striking difference between the two
recipient mouse strains. Whereas mammary artery grafts recovered 30 days after
reconstitution with 5×107human PBMCs from C57BL/6–Rag2−/−γc−/−recipients
showed significant amounts of intimal proliferation (44.58±11.08% luminal occlusion/
n=5), C.B17–SCID/beige mice showed significantly less intima proliferation after
reconstitution with equal levels of human PBMCs (28.49±7.95% luminal occlusion/
n=5) (Fig. 1C, D, Fig. 4). In addition, variations among individual experiments within
the respective experimental group were much smaller in C57BL/6–Rag2−/−γc−/−
recipients as compared to C.B17–SCID/beige recipients.
In this study, we compared the engraftment of human PBMCs in C.
B-17–SCID/beige and C57BL/6–Rag2−/−γc−/−mice and their rejec-
tion response to a human artery graft. To allow direct comparisons in
these two mouse strains, a number of critical parameters were held
constant throughout the study, including age at the time of
engraftment and an identical number of input cells from each PBMC
source in a given experiment. On many occasions, cells from identical
buffy-coats were injected on the same day into mice of the two
different strains. Here we can show that (1) after reconstitution with
unfractionated human PBMCs C57BL/6–Rag2−/−γc−/−mice revealed
Fig. 1. For the morphometric analysis of the degree of intimal thickening Miller's Elastin van Gieson stained sections were used. Areas within the lumen and the internal elastic
lamina were circumscribed manually andmeasured. Human artery grafts recovered from C.B17–SCID/beige recipients on day 30after transplantation displayed vascular lesions even
in the absence of human PBMCs (A), whereas C57BL/6–Rag2−/−γc−/−recipients did not show significant lesions (B). Panel (C) shows a human artery graft recovered from a C.B17–
SCID/beige recipient (n=5) reconstituted with 5×107human PBMCs on day 30 after reconstitution; C57BL/6–Rag2−/−γc−/−recipients (n=5) reconstituted with the same amount
of human PBMCs showed significant more intima proliferation (D) (original magnification ×200).
S. Abele-Ohl et al. / Transplant Immunology 23 (2010) 59–64
Author's personal copy
a more reliable reconstitution as determined by the presence of
human CD45+cells within the peripheral blood and spleen compared
to C.B-17–SCID/beige mice. In addition (2) levels of human IgG and
IgM within the peripheral blood were markedly higher in C57BL/6–
Rag2−/−γc−/−recipients. Furthermore, (3) transplant arteriosclero-
sis after reconstitution with human PBMCs was more pronounced and
reliable in C57BL/6–Rag2−/−γc−/−recipients as compared to C.B-17–
SCID/beige mice, which also demonstrated vascular lesions in the
absence of reconstitution with human PBMCs.
The initial human artery transplantation model in a humanized
mouse using C.B-17–SCID/beige mice as recipients was developed by
Lorber et al.  to overcome species specific differences between
mice and humans, such as differences in cell signalling e.g. in the
expressionof MHCmolecules.Rodent endothelial cells expressmainly
MHC II whereas human endothelial cells express MHC I and MHC II
[25,26]. In addition, there are structural differences between mouse
and human vessels, e.g. the integrity of the human vascular media in
clinical heart transplantation is mostly preserved, whereas vascular
smooth muscle cells (VSMCs) of the mouse media disappear during
the rejection response . These problems seemed to have been
overcome by implanting a human artery into a ‘humanized’ mouse
recipient and indeed the authors managed to demonstrate that the
Fig. 2. (A and B) FACS analysis for human lymphocyte detection within the peripheral blood and mouse spleen after reconstitution with human PBMCs i.p. into the respective C.B17–
SCID/beige (A) or C57BL/6–Rag2−/−γc−/−recipients (B). Results are given as percentage of human leukocytes of total circulating leukocytes (CD45). The positive control was
peripheral human blood (A) or a mixture of human blood and mouse blood (B). (C) The diagram shows average amounts of human CD45+cells detected by FACS analysis in the
respective experimental groups. There were low numbers of detected human cells with blood and spleen of C.B17–SCID/beige recipients, whereas C57BL/6–Rag2−/−γc−/−
recipients showed significant numbers of human cell reconstitution within blood and spleen.
Fig. 3. Human IgG and IgM showed much higher concentrations within the peripheral
blood of C57BL/6-Rag2−/−γc−/−recipients compared to C.B17-SCID/beige.
S. Abele-Ohl et al. / Transplant Immunology 23 (2010) 59–64
Author's personal copy
vessel injury was specific to the human arterial segments and was
mediated by the human PBMCs . However, results of the present
study show that after successful reconstitution, rejection responses of
human arterial grafts implanted into C.B-17–SCID/beige recipients
were very variable and on a significantly lower level as compared to
C57BL/6–Rag2−/−γc−/−mice, when identical numbers of human
PBMCs were injected. One aspect that may account for this difference
is the deficiency of the interleukin-2 receptor (IL-2R) γ-chain locus
that is required for high-affinity binding of the receptors for IL-2, IL-4,
IL-7, IL-9, IL-15, and IL-21 and is essential for their signalling and
function . This mutation renders RAG2−/−mice more deficient in
NK cells, as well as causing deficiencies in T- and B-cell development
and function and may therefore provide a critical environment for
enhanced human PBMC development in C57BL/6–Rag2−/−γc−/−
mice as demonstrated in this report. However, defects in NK-cell
function conferred by the ‘beige’ mutation of the C.B-17–SCID
recipients did not result in similar levels of reconstitution in the
recipients of human vessel transplants. In addition, although C.B-17–
SCID/beige mice were screened for mu IgG and IgM before each
experiment to exclude ‘leaky’ C.B-17–SCID/beige mice some tend to
become leaky later on as a consequence of reactivation of single T-cell
clones. This circumstance also may have prevented better engraft-
ment of human PBMCs in C.B-17–SCID/beige as compared to C57BL/
Arterial grafts implanted in C.B-17–SCID/beige recipients dis-
played variable levels of intima proliferation after reconstitution with
similar numbers of human PBMCs. Interestingly, several grafts
demonstrated strong vascular lesions in the absence of reconstitution
with human PBMCs. In contrast, similar experiments using C57BL/6–
Rag2−/−γc−/−mice showed only discrete signs of intima prolifera-
tion in the absence of human PBMCs and more constant results after
reconstitution withhuman PBMCs. One explanation for this difference
may be the fact that C.B-17–SCID/beigemice can become leaky later in
life, as already discussed and that NK-cell function is not as impaired
as in C57BL/6–Rag2−/−γc−/−mice. The significantly higher level of
human immunoglobulins in these mice is further evidence for a better
engrafting of the hu PBMCs in this mouse strain.
Engraftment levels of human PBMCs in C.B-17–SCID/beige mice
are discussed controversially in the literature [2,28]. Some groups
favour C.B-17–SCID/beige mice as the strain of choice for the transfer
of a human adaptive immune system , others demonstrated
variable and mostly low level engraftment of human PBMCs by using
this mouse strain . Results of the present study support the latter
view as we could only achieve very low levels of human PBMC
engraftment in C.B-17–SCID/beige mice. Recently, it was shown by
two groups that Rag2−/−γc−/−mice supported B-cell, DC and T cell
development, following engraftment of human stem cells (HSC)
[29,30]. However, for the current report, human PBMCs were used for
reconstitution of the Rag2−/−γc−/−mice and our results also support
sufficient engraftment of T cells as shown in the peripheral blood and
spleen. In addition, significantly higher amounts of human IgG and
IgM were detected in Rag2−/−γc−/−mice than in the C.B-17–SCID/
beige mice and histologic analysis of the human artery graft revealed
significant amounts of human CD45+cells (data not shown).
There are two experimental-setup-specific parameters that need
monitoring: Firstly, the fact that human mammary artery segments
display variable amounts of ordinary arteriosclerosis, at the beginning
of each experiment. These differences were taken into account by
analysing the human vessel before implantation in the respective
recipient and by comparing these results to measurements performed
after explanation of the arterial graft at the end of each experiment. In
addition it was shown in previous studies, that alloimmune-mediated
intimal injury and vascular remodelling is somewhat independent of
pre-existing coronary atherosclerosis . Secondly, although experi-
ments were performed in groups, there were differences in HLA-
mismatches between the implanted human artery segments and the
respective buffy-coats used for reconstitution. As both, human artery
segments and buffy coats from single donors, were tissue typed for
each experiment, data revealed that there was an average of 3.7 HLA
mismatches between arterial grafts and PBMCs used for reconstitu-
tion in both experimental groups (data not shown).
Survival rates after surgery were on a similar level for both
experimental groups (N85%) with thrombosis of the graft being the
most frequent complication. However, mice from both strains
analysed occasionally became ill during adult life and required
premature euthanasia for human reasons if they failed to reconstitute
or had very low engraftment levels (b0.1%). These mice were not used
in the functional analysis experiments.
Optimizing ‘humanized’ mouse models to investigate underlying
mechanisms of chronic allograft rejection is paramount to a more
progression. The current study reports a comparison of two different
recipient mouse strains in a mouse model of human artery transplan-
offer technical advantages over C.B-17–SCID/beige recipients as they
much more readily accept human blood PBMCs, show improved
reconstitution rates with lower levels of human PBMCs and more
lesions were not detected in C57BL/6–Rag2−/−γc−/−recipients in the
absence of cell transfer. Therefore, the use of C57BL/6–Rag2−/−γc−/−
a humanized mouse model.
The authors would like to thank Mr Johannes Roesch and Mrs.
Regina Müller for expert technical assistance. We would also like to
thank Professor Stephan von Hoersten and the staff of the animal
facility of the University of Erlangen-Nürnberg for their expert care of
animals used for this study.
This work was supported by grants from the IZKF of the University
of Erlangen-Nürnberg, the GRK1071 and the ADUMED-Foundation.
 Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW. Othieno FA, et al.
Humanized mice mount specific adaptive and innate immune responses to EBV
and TSST-1. Nat Med 2006;12(11):1316–22.
Fig. 4. Human artery grafts recovered from C.B17–SCID/beige recipients on day 30 after
transplantation displayed vascular lesions even in the absence of human PBMCs,
whereas C57BL/6–Rag2−/−γc−/−recipients did not show significant lesions. C57BL/6–
Rag2−/−γc−/−recipients reconstituted with the same amount of human PBMCs
showed significant more intima proliferation than the C.B17–SCID/beige recipients
(*=pb0.05 vs. unreconstituted C.B17–SCID/beige; **=pb0.05 vs. reconstituted C.
S. Abele-Ohl et al. / Transplant Immunology 23 (2010) 59–64
Author's personal copy Download full-text
 Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical
research. Nat Rev Immunol 2007;7(2):118–30.
 Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH. Proteasome
inhibition reduces superantigen-mediated T cell activation and the severity of
psoriasis in a SCID-hu model. J Clin Invest 2002;109(5):671–9.
 Pober JS, Bothwell AL, Lorber MI, McNiff JM, Schechner JS, Tellides G.
Immunopathology of human T cell responses to skin, artery and endothelial cell
grafts in the human peripheral blood lymphocyte/severe combined immunode-
ficient mouse. Springer Semin Immunopathol 2003;25(2):167–80.
 Banuelos SJ, Shultz LD, Greiner DL, Burzenski LM, Gott B, Lyons BL, et al. Rejection
of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive
human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1
(null) mice. Clin Immunol 2004;112(3):273–83.
 McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL.The
SCID-hu mouse: murine model for the analysis of human hematolymphoid
differentiation and function. Science 1988;241(4873):1632–9 Sep 23.
 Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, McCune JM. Long-term
human hematopoiesis in the SCID-hu mouse. J Exp Med 1990;172(4):1055–63.
 Kyoizumi S, Baum CM, Kaneshima H, McCune JM, Yee EJ, Namikawa R.
Implantation and maintenance of functional human bone marrow in SCID-hu
mice. Blood 1992;79(7):1704–11.
 Carballido JM, Namikawa R, Carballido-Perrig N, Antonenko S, Roncarolo MG, de
Vries JE. Generation of primary antigen-specific human T- and B-cell responses in
immunocompetent SCID-hu mice. Nat Med 2000;6(1):103–6.
 Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human
immune system to mice with severe combined immunodeficiency. Nature
 Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL, Shultz LD. High levels
of human peripheral blood mononuclear cell engraftment and enhanced
susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-
scid/scid mice. J Infect Dis 1995;172(4):974–82.
 Tereb DA, Kirkiles-Smith NC, Kim RW, Wang Y, Rudic RD, Schechner JS, et al.
Human T cells infiltrate and injure pig coronary artery grafts with activated but
not quiescent endothelium in immunodeficient mouse hosts. Transplantation
 Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE. Cytokine
stimulation of multilineage hematopoiesis from immature human cells engrafted
in SCID mice. Science 1992;255(5048):1137–41.
 Pflumio F, Izac B, Katz A, Shultz LD, Vainchenker W, Coulombel L. Phenotype and
function of human hematopoietic cells engrafting immune-deficient CB17-severe
combined immunodeficiency mice and nonobese diabetic-severe combined
immunodeficiency mice after transplantation of human cord blood mononuclear
cells. Blood 1996;88(10):3731–40.
 Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP. Thrasher AJ. Enhanced
human cell engraftment in mice deficient in RAG2 and the common cytokine
receptor gamma chain. Br J Haematol 1998;103(2):335–42.
 Mazurier F, Fontanellas A, Salesse S, Taine L, Landriau S, Moreau-Gaudry F, et al. A
novel immunodeficient mouse model–RAG2 x common cytokine receptor gamma
chain double mutants–requiring exogenous cytokine administration for human
hematopoietic stem cell engraftment. J Interferon Cytokine Res 1999;19(5):
 Murray AG, Petzelbauer P, Hughes CC, Costa J, Askenase P, Pober JS. Human T-cell-
mediated destruction of allogeneic dermal microvessels in a severe combined
immunodeficient mouse. Proc Natl Acad Sci U S A 1994;91(19):9146–50.
 Timmermann W, Gassel HJ, Ulrichs K, Zhong R. Thiede A. Organ transplantation in
rats and mice:Microsurgical techniques and immunological principles. Berlin; 1998.
 Shiao SL, McNiff JM, Pober JS. Memory T cells and their costimulators in human
allograft injury. J Immunol 2005;175(8):4886–96.
 Christianson SW, Greiner DL, Schweitzer IB, Gott B, Beamer GL, Schweitzer PA,
et al. Role of natural killer cells on engraftment of human lymphoid cells and on
metastasis of human T-lymphoblastoid leukemia cells in C57BL/6J-scid mice and
in C57BL/6J-scid bg mice. Cell Immunol 1996;171(2):186–99.
 Colucci F, Soudais C, Rosmaraki E, Vanes L, Tybulewicz VL, Di Santo JP. Dissecting
NK cell development using a novel alymphoid mouse model: investigating the
role of the c-abl proto-oncogene in murine NK cell differentiation. J Immunol
 Yacoub-Youssef H, Marcheix B, Calise D, Thiers JC, Therville N, Benoist H, et al.
Engraftment of human T, B and NK cells in CB.17 SCID/beige mice by transfer of
human spleen cells. Transpl Immunol 2005;15(2):157–64.
 Lorber MI, Wilson JH, Robert ME, Schechner JS, Kirkiles N, Qian HY, et al. Human
allogeneic vascular rejection after arterial transplantation and peripheral lymphoid
reconstitution in severe combined immunodeficient mice. Transplantation 1999;67
 Ensminger SM, Billing JS, Morris PJ, Wood KJ. Development of a combined cardiac
and aortic transplant model to investigate the development of transplant
arteriosclerosis in the mouse. J Heart Lung Transplant 2000;19(11):1039–46.
 Ferry B, Halttunen J, Leszczynski D, Schellekens H. vd Meide P.H., Hayry P. Impact
of class II major histocompatibility complex antigen expression on the
immunogenic potential of isolated rat vascular endothelial cells. Transplantation
 Fabre JW, Barclay AN, Mason DW. Class II major histocompatibility complex
antigens expressed on blood vascular endothelial cells. Transplantation 1983;36
 Yacoub-Youssef H, Marcheix B, Calise D, Thiers JC, Benoist H, Blaes N, et al. Chronic
vascular rejection: histologic comparison between two murine experimental
models. Transplant Proc 2005;37(6):2886–7.
 Berney T, Molano RD, Pileggi A, Cattan P, Li H, Ricordi C, et al. Patterns of
engraftment in different strains of immunodeficient mice reconstituted with
human peripheral blood lymphocytes. Transplantation 2001;72(1):133–40.
 Lepus CM, Gibson TF, Gerber SA, Kawikova I, Szczepanik M, Hossain J, et al.
Comparison of human fetal liver, umbilical cord blood, and adult blood
hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-
gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol 2009;70
 Gimeno R, Weijer K, Voordouw A, Uittenbogaart CH, Legrand N, Alves NL, et al.
Monitoring the effect of gene silencing by RNA interference in human CD34+ cells
injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in
developing T cells. Blood 2004;104(13):3886–93.
 Wang Y, Ahmad U, Yi T, Zhao L, Lorber MI, Pober JS, et al. Alloimmune-mediated
vascular remodeling of human coronary artery grafts in immunodeficient mouse
recipients is independent of preexisting atherosclerosis. Transplantation 2007;83
S. Abele-Ohl et al. / Transplant Immunology 23 (2010) 59–64